Tag: Prescription Drugs

SC casirivimab and imdevimab linked to reduced 28-day hospitalization or death for high-risk outpatients with mild to moderate COVID-19

No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept

But no indication of protection against all-cause death, kidney disease progression, or kidney failure; increased risk of genital infection

Any DMARD use recorded at 56 percent of rheumatologist visits and 30 percent of primary care provider visits

After 16 weeks, 76.8 and 17.9 percent in the placebo and mavacamten groups, respectively, decided to proceed with or were eligible for surgery

Pain improved with ultrasound-guided intra-articular hip injection of corticosteroid and local anesthetic added to best current treatment

But, though difference is small, tranexamic acid not noninferior to placebo for primary safety outcome of composite cardiovascular outcome

Findings observed in patients with complicated urinary tract infection or acute pyelonephritis

Also no decrease seen in prolonged ED visits for patients with COVID-19 symptoms for up to seven days, at least one risk factor for progression

Despite increases in units per prescription, the amount of buprenorphine dispensed to Medicaid beneficiaries decreased early in the pandemic